PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma.

Blood Adv · 2023 · PMC10582835 · PMID 37327122

Europe PMC DOI

hedged sentence

0.2230

closest p · 4.5× alpha

0.2230

boldest claim

The sentences

showed a trendP = .223not close (p > 0.1)

Granta-519 also showed a trend toward rescue with BAX knockdown ( P = .223) ( supplemental Figure 6 B), whereas neither protein knockdown rescued Maver-1 cells ( supplemental Figure 6 D).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.